ArticleBMC endocrine disorders2025
Clinical and serological characteristics of type 3 APS, isolated T1DM and LADY/LADA.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are few studies comparing Type 3 autoimmune polyendocrine syndromes (APS) with isolated type 1 diabetes mellitus (T1DM), latent autoimmune diabetes in youth (LADY), and latent autoimmune diabetes in adults (LADA) in the Chinese population. This study aims to report the clinical and serological characteristics of Chinese patients with Type 3 APS, isolated T1DM, LADY and LADA, and to make comparisons.
methodsThis study retrospectively analyzed the clinical and serological characteristics of hospitalized patients with Type 3 APS, T1DM, LADY and LADA who were admitted to our center.
resultsA total of 69 patients were included in this study, comprising 18 with Type 3 APS, 20 with T1DM, and 31 with LADY/LADA. The majority of Type 3 APS patients were female, whereas T1DM and LADY/LADA groups had a higher proportion of males. The median age and onset age of diabetes in the Type 3 APS group were 35.50 (31.00, 52.50) years and 30.50 (26.75, 47.25) years, respectively. Diabetes and autoimmune thyroid disease (AITD) in Type 3 APS patients may occur simultaneously or several years apart. The levels of GADAb and thyroid autoantibodies in Type 3 APS patients were often higher.
conclusionsType 3 APS exhibits differences when compared to isolated T1DM and LADY/LADA. For patients with TIDM or LADY/LADA, especially female patients, those over 30 years old or with high-titer GADAb, attention should be paid to screening for APS 3, including the detection of thyroid autoantibodies. Patients suspected or confirmed to have Type 3 APS need long-term follow-up. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.